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Tuberculosis (TB) causes significant morbidity and mortality in high-income countries with foreign-born individuals
bearing a disproportionate burden of the overall TB case burden in these countries. In this review of tuberculosis
and migration we discuss the impact of migration on the epidemiology of TB in low burden countries, describe the
various screening strategies to address this issue, review the yield and cost-effectiveness of these programs and
describe the gaps in knowledge as well as possible future solutions.
The reasons for the TB burden in the migrant population are likely to be the reactivation of remotely-acquired
latent tuberculosis infection (LTBI) following migration from low/intermediate-income high TB burden settings to
high-income, low TB burden countries.
TB control in high-income countries has historically focused on the early identification and treatment of active TB
with accompanying contact-tracing. In the face of the TB case-load in migrant populations, however, there is
ongoing discussion about how best to identify TB in migrant populations. In general, countries have generally
focused on two methods: identification of active TB (either at/post-arrival or increasingly pre-arrival in countries of
origin) and secondly, conditionally supported by WHO guidance, through identifying LTBI in migrants from high TB
burden countries. Although health-economic analyses have shown that TB control in high income settings would
benefit from providing targeted LTBI screening and treatment to certain migrants from high TB burden countries,
implementation issues and barriers such as sub-optimal treatment completion will need to be addressed to ensure
program efficacy.
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In this review (see Table 1) we first analyse the burden
of tuberculosis (TB) in foreign-born, migrant popula-
tions before going on to discuss the drivers of the
current TB epidemiology in these populations focusing
on migration patterns, the importance of reactivation of
latent tuberculosis infection as compared to the burden
of imported active TB and molecular genotyping data
underpinning these studies. We then go on discuss, in
detail, the methods, outcomes, and cost-effectiveness of* Correspondence: mp426@le.ac.uk
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Tuberculosis (TB) remains a ‘global health emergency’
[1]. Although much of the burden is concentrated in
high-burden settings in Asia and Africa (which make up
58 % and 28 % of all cases respectively) [2], TB continues
to be of concern in high-income nations. In the 34 high-
income Organisation for Economic Cooperation and
Development (OECD) countries, TB incidence fell by a
median of 4.7 % per year (between 1995 and 2004) decel-
erating to 3.0 % per year between 2005 and 2014 [3] –
making TB elimination more difficult to attain [4].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Key messages about tuberculosis and migration in
high-income countries
• Tuberculosis continues to be a public health concern in high-income
countries
• Tuberculosis burden in high-income countries is primarily amongst the
foreign-born, migrant population
• The reasons underlying this burden are the interaction of migration
from high TB burden countries and the reactivation of remotely
acquire latent tuberculosis infection in the first five years after arrival
• Genotyping data suggests that there is relatively little transmission in
migrant communities in the receiving country
• Methods of TB control in migrant population have historically focused
on identifying active tuberculosis but the yields for this remain
relatively low
• Screening migrants for latent tuberculosis infection may have a higher
yield although implementation may be difficult
• The health economics of screening migrants for active and/or latent
tuberculosis is a topic of much debate
• Targeted pre-arrival screening for active TB and post arrival screening
for latent tuberculosis infection in migrants from intermediate/high TB
burden settings may provide the most cost-effective solution
• Implementation of programmatic screening is limited by uptake,
acceptance and completion of therapy
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income countries hide an important disparity: while
local-born cases have remained static or decreased,
foreign-born cases have decreased more slowly or in-
creased. From 2000 to 2013, local-born TB cases de-
creased by half (median 51.3 %; IQR −64.3 – -35.3 %)
whilst foreign-born case notifications increased margin-
ally (median 2.3 %; IQR −36.7 – +40.4 %) [5–10]. In just
under half of the high-income OECD countries foreign-
born TB cases increased [5–10]. Consequently foreign-
born individuals, in 2013, made up over half of all TB
cases (median 52.0 %; IQR 31.4–73.9 %; Fig. 1) [5–11]
with incidence rates 8.7-18.4 times that seen in the
local-born population [7, 9, 10, 12].
Drilling down further into the patterns TB notifica-
tions in the foreign-born population in high-income
countries reveals information about key risk groups with
the highest incidence and risk of active TB following
migration: migrants from Asia and Africa where the
burden of TB is moderate/high, recent migrants (within
5 years of arrival), refugees and individuals with comor-
bidities (such as HIV infection and diabetes mellitus)
[7, 9, 10, 12, 13].
Migration and reactivation of latent TB infection:
key drivers of tuberculosis in migrants in high-
income countries
Understanding the scale and nature of migration to
high-income countries
In 2013, United Nations figures showed that the global
number of migrants was 232 million – a 50 % increaseover the preceding two decades [14] with a concomitant
change in the pattern of sending countries [15] as glo-
balisation, conflict, and financial reasons have become
increasingly important drivers of migration flows. This
has resulted in more permanent migrants moving from
low/medium income, higher TB burden, countries to
high-income developed, lower TB burden, countries in-
cluding USA, Canada, Australia and Western European
nations although migrants are not necessarily represen-
tative of the population in the country of origin [15].
Top migrant sending countries for each high-income
country will vary according to historic, linguistic, cul-
tural links and geographic proximity. In the UK a signifi-
cant proportion of the foreign-born migrants arrive from
former colonies in Sub-Saharan Africa and the Indian
Subcontinent whereas in the US the majority of the
foreign-born population originate from Central and
South America [16]. As a consequence of migration, in
high-income OECD countries, the median proportion of
the population that is foreign-born is estimated to be
13.7 % (IQR 10.8-18.4 %) [17].
Reactivation of latent TB infection in determining TB
burden in migrants
The TB burden observed in foreign-born individuals oc-
curs due to one of three reasons: (1) migrants from
overseas must either have active TB on arrival, (2) mi-
grants have remotely-acquired latent TB infection which
reactivates post-arrival or (3) migrants acquire TB, fol-
lowing arrival, through local transmission (Fig. 2).
Active TB disease in migrants on arrival in the receiving
country
Surveillance data, and findings from previous meta-
analyses (Table 2), have shown that the proportion of
migrants with active TB present at the time of migration
is relatively small (0.35 %) [18, 19].
High prevalence of latent TB infection and risk of
progression to active disease
Latent TB prevalence figures in migrants are primarily
derived from cross-sectional studies where, depending
on the specific population tested and the diagnostic tool
used, 5-72 % of migrants test positive for LTBI [20–43];
this is independently associated with increasing age and
TB incidence in country-of-origin [41, 42, 44]. One can
therefore infer that it is both the cumulative duration of
exposure and the TB burden in the source country
which determines whether individuals will have LTBI
[29, 41, 42, 44, 45]. Migrants with LTBI are coming to
lower incidence settings and in the initial years fol-
lowing arrival in the destination country, have a
higher risk of LTBI reactivation which decreases
slowly over time but remains higher than rates in the
Fig. 1 Percentage of tuberculosis notifications in the foreign-born for selected OECD high-income countries
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Fig. 2 Schematic diagram of migration, factors determining how incident active tuberculosis occurs and methods of screening migrants.
Footnote: As a by-product of post-arrival latent TB screening, some cases of prevalent active TB may be identified
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activation in the initial one to two years after mi-
grants arrive likely reflects latent tuberculosis infection
which has been acquired in their country of origin shortly
before migration although there is also likely to be an on-
going complex interplay, in the destination country, of
host (such as age, and comorbidities including diabetes
mellitus) and environmental factors (such as nutri-
tional status) which contribute to the observed epi-
demiology. Understanding the natural history of TB
in recently arrived migrants is important when we are
considering how best to implement TB control in this
population.
Whilst the literature has expanded rapidly in respect
of cross-sectional data on LTBI prevalence, longitudinal
data on the risk of migrants with diagnosed, untreated,
LTBI progressing to active TB disease remain limited
partially due to low numbers of chemoprophylaxis-naïve
patients (due to recommendations to treat, and notTable 2 Yields for active tuberculosis from previous
meta-analyses
Author Year Yield for active tuberculosis (%)
Overall Pre-arrival At/post-arrival
Klinkenberg [19] 2009 0.35 1.21 0.31
0.51
Arshad [18] 2010 0.35 - 0.35
Aldridge [71] 2014 0.22 0.22 -withhold treatment from, individuals identified with la-
tent TB such as in the UK) and because studies to an-
swer this research question need a large sample size and
long duration of follow-up. A UK study followed mi-
grants, predominantly from the Indian Subcontinent,
and found a TB progression rate of 16.3 % amongst un-
treated tuberculin skin test (TST) positive patients over
a 15 year period following UK arrival [49]. The risk was
significantly higher for young migrants (aged 16–19) and
for women [49]. However this study did not adjust inci-
dence rates for travel back to countries of origin nor
underlying medical comorbidities. A Norwegian study of
asylum seekers found a progression rate of 1.1 % over a
follow-up period of up to 32 months [50]. By contrast,
Marks and colleagues evaluated a large cohort of pre-
dominantly Southeast Asian migrants, with no evidence
of active TB, over a mean follow-up of 10.3 years post-
arrival in Australia and found that 0.12 % with a positive
TST progressed to active TB disease per year [51]. Fur-
ther work is needed to determine both the overall risk of
progression from LTBI to active TB disease in migrants
as well as the contribution of concomitant medical co-
morbidities and demographics such as diabetes mellitus,
chronic kidney disease and age. Diabetes mellitus and
chronic kidney disease are more common in migrant
populations and significantly increase the risk of re-
activation from LTBI to active TB [13, 52]. This is
likely to result in increasing TB notifications in the
foreign-born, migrant populations, particularly as the
migrant population ages, and this will, therefore, need
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control programmes [13].
An additional issue which is likely to play a part in de-
termining TB epidemiology in migrant populations is
the acquisition, and subsequent reactivation, of LTBI fol-
lowing re-exposure during travel back to their countries
of origin. Previous work in this area has indicated that
travel to high TB burden countries increases the risk of
acquiring LTBI with the risk increasing with more pro-
longed travel and a higher TB burden in the country vis-
ited [53]. Although there is a paucity of data on the
proportion of TB acquired through travel, published
work suggests this could be anywhere between 20 % and
50 % [54, 55]. However further prospective research in
this area is needed to more accurately quantify the risk.
Using molecular genotyping to distinguish reactivation of
latent TB and recent transmission of active TB in migrants
In order to distinguish reactivation of remotely acquired
LTBI from TB transmission, authors have genotyped
DNA isolated from M. tuberculosis cases in foreign-born
individuals. Here, individuals with a TB isolate with a
clustered DNA pattern that matches at least one other
case in the cohort is attributed to recent transmission
whereas cases with unique, DNA patterns are thought to
arise due to the reactivation of LTBI [56, 57]. In a large
meta-analysis across a range of TB burden settings,
foreign-born individuals were significantly less likely to
have a clustered isolate as compared to local-born indi-
viduals (25 % versus 45.8 % clustered respectively) [57].
Moreover, there is little evidence that the foreign-born
population transmit TB to the local born population
[58]. These data, in conjunction with TB surveillance
data, appear to highlight the importance of reactivating
LTBI amongst migrants in determining TB epidemiology
in high-income countries and, therefore, the need to
have appropriate control measures in place.
Tuberculosis control with a special focus on
migrants
Globally, TB control policies focus on quickly diagnosing
and treating individuals with active TB. Additionally in
high-income countries this is complemented by the
contact-tracing of household contacts of smear-positive
cases with the overall aim of reducing onward transmis-
sion. However this method of TB control does not fully
address the potential source of reactivation of remotely
acquired LTBI progressing to active TB disease – such
as that seen in migrants. Dynamic transmission models
have been used to study the impact of chemoprophylaxis
for LTBI on global TB control and concluded that
concurrently targeting individuals with active TB dis-
ease and individuals with LTBI will augment TB control
[59–63]. The growing importance of tackling LTBI isreflected by recent WHO guidelines which conditionally
recommend migrants from high TB burden countries are
offered screening and LTBI treatment [64].
Migrant screening practices and their outcomes in
high-income countries
Several authors have recently reviewed the migrant TB
screening programmes in high-income countries. Each
program is different and they differ by whether screen-
ing is done for active or latent TB (or both), when
screening is performed in relation to arrival in the
host country, which groups of migrants are screened
(refugees or other migrants groups; which countries
of origin) and which tools are used to screen for ac-
tive and latent TB (see Table 3) [65–69]. It should,
however, be borne in mind that much of the available
data relates to documented migrants and there remains
ongoing difficulty in collecting data on undocumented mi-
grant who bypass standard screening protocols.
Screening practices for active tuberculosis
Most OECD high-income countries screen migrants for
active TB although the specifics of how this is performed
vary significantly across countries. Most active TB
screening programs in Western Europe are performed
on or soon after arrival with a chest radiograph (CXR).
Other countries such as Canada, the US, Australia, New
Zealand and recently the UK, screen for active TB with a
CXR prior to arrival. If the CXR is abnormal a sputum
smear and culture are performed. Those found to have
active TB are treated prior to arrival and granted permis-
sion to enter the country if cultures are negative at the
end of treatment. Those found to have an abnormal
CXR but negative sputum cultures or those with prior
treated TB are followed after arrival in a post-landing
surveillance program [65–70].
The criteria for which migrant groups are screened is
also highly variable [67, 69]. Alvarez and colleagues
found that countries differed in which migrants were se-
lected for screening basing their decision on a number
of factors including: type of migrant (e.g. refugee, stu-
dents, workers), duration of stay, intended occupation or
TB burden in country of origin [67]. In a large survey of
OECD countries, the authors identified heterogeneity in
source country incidence thresholds for screening al-
though, in general, migrants arriving from high TB bur-
den settings were preferentially selected for screening
[69]. The reasons for this remain unclear but it may
reflect a lack of evidence in this area.
Outcomes of screening for active TB
Whilst screening for active TB is frequently undertaken,
there is a lack of trial data for its effectiveness as a public
health intervention. Policy decisions therefore rely on
Table 3 Potential strengths and weaknesses of different migrant screening methods
Screening methodology
Screening for active tuberculosis Screening for latent tuberculosis infection
Screening tool used Chest x-ray Tuberculin skin test
Interferon gamma release assay
Screening location Pre-arrival Post-arrival
At arrival
Post-arrival
Strengths Able to identify active TB Identifies latent TB before reactivation occurs
Able to identify infectious individuals Can be built into community programmes
Can be integrated into immigration processes Targeted screening likely to be cost-effective
Weaknesses Low yields for active TB Programmatically difficult to implement
Uncertain cost-effectiveness (unless screening targeted) Numbers accepting and completing treatment may
be suboptimal
Does not identify patients with latent TB who can go
on to reactivate
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Pre-arrival screening, in country of origin, is part of the
immigration process of several high-income countries –
including the US, Australia, Canada and the UK. Aldridge
and colleagues undertook a detailed systematic review and
meta-analysis on the yields of active TB through pre-
arrival screening. They found that the overall yield for cul-
ture positive active TB was 0.22 % (219 cases/100,000)
[71]; the yield for culture positive TB increased with in-
creasing TB prevalence in country of origin [71] suggest-
ing that setting an incidence threshold for pre-arrival
screening of migrants may be needed to ensure cost-
effective use of resources. Klinkenberg et al. reviewed the
yields for active TB at different stages of the immigration
process and found that the yields for pre-arrival, as com-
pared to post-arrival, screening were higher (1.21 % versus
0.31 % respectively) although these data were based en-
tirely on non-EU studies [19]. A recently published ana-
lysis of the US pre-arrival screening programme found
that 4032 cases of culture positive TB were diagnosed
amongst 1,561,460 migrants screened (yield 0.26 %) result-
ing in a reduction in the number of TB cases diagnosed
amongst migrants within one year of arrival in the US
[43]. The UK pre-arrival screening programme yield for
active TB has steadily increased from 0.05 % in 2006 to
0.16 % in 2014 which most likely reflects the use of spu-
tum cultures [72, 73].
Post-arrival screening for active TB involves chest
radiography once the migrant has arrived in the host
country. Two systematic reviews have evaluated the out-
comes and yields for active TB in high-income countries
[18, 19]. Arshad et al. reviewed 22 studies comprising
2,620,739 migrants and found that the overall yield for
post-arrival screening was 0.35 % with higher yields inmigrants from Africa and Asia [18]. Klinkenberg and
colleagues reviewed 40 studies and found that the yields
for post-arrival screening, which were lower than that
for pre-arrival screening, ranged from 0.20 % to 0.36 %
depending on the specific setting in which screening was
undertaken [19].
Previous work has shown that the current models of
active TB screening have weaknesses including: individ-
uals not completing the screening processes, limited
yields for active disease and an inability to identify active
TB occurring through LTBI reactivation [13].
Screening practices for latent tuberculosis
Whilst most countries offer some form of screening for
active TB, screening for LTBI is much less commonly
performed [69]. High-income countries that screen for
LTBI usually undertake this post-arrival with a tubercu-
lin skin test (TST) or an interferon gamma release assay
(IGRA) [69, 74].
For reasons of practicality and cost-effectiveness, most
high-income countries attempt to limit the eligible
population to refugees or asylum seekers or those indi-
viduals arriving from high TB burden settings [69]. How-
ever, countries vary considerably in their definition of a
high TB burden setting for the purposes of migrant
screening [69]; the UK has taken a decision to screen
migrants arriving from countries in Sub-Saharan Africa
or those countries with a TB incidence above 150 per
100,000 whereas Canada screens at a lower threshold of
30/100,000 but only migrants with increased risk of re-
activation. Given the prevalence of comorbidities in the
migrant population (such as diabetes mellitus,) which in-
crease the risk of reactivation, these factors will likely
need to be taken into account when determining which
migrants to screen. At the present time, however, the
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about the optimal screening threshold which balances
the need to identify the majority of LTBI with cost
effectiveness.
Outcomes of screening for latent tuberculosis infection
Successful screening for LTBI involves a number of key
interlinked steps including the accurate identification of
migrants, appropriate screening of migrants, initiation of
chemoprophylaxis and completion of therapy. However
most of the data on LTBI screening outcomes come
from cross-sectional studies which have been conducted
with the primary aim of calculating the prevalence of
LTBI in migrants (estimated at around 25-30 % in young
adult migrants from high incidence countries) [20–43].
However, there is less data on the other elements of the
screening pathway – including uptake, and completion,
of chemoprophylaxis. A Canadian group recently
reviewed the data on LTBI screening effectiveness and
found that migrants dropped out at each step of the
screening pathway so that overall only 31 % of the co-
hort completed the programme successfully highlighting
the need for research into interventions to optimise the
LTBI screening pathway [75]. Programmatically, at a na-
tional level, there is little observational data on the im-
pact of LTBI screening on TB notifications in migrants
although the recently commenced UK national migrant
screening programme will provide this useful data in the
next few years [76].
Health economics of migrant screening
Whilst the programmatic outcomes of migrant screening
are important, a key consideration for policy-makers and
clinicians is cost-effectiveness. Several studies have ex-
plored the cost-effectiveness of migrant screening for TB
although they have focused on different aspects of
screening including whether to screen for active or la-
tent TB, which migrant groups to screen and how to
screen [41, 42, 77–86].
Cost-effectiveness of screening for active and latent
tuberculosis
Screening migrants for active TB is widely implemented
by high-income countries albeit with different models of
care. However there are few studies formally examining
the cost-effectiveness of this intervention. Previous stud-
ies have come to differing conclusions about the cost-
effectiveness of screening migrants for active TB.
Schwartzman and colleagues modelled the comparative
cost-effectiveness of migrant screening using chest radi-
ography versus tuberculin skin test (versus no screening)
and found that in migrants with a high prevalence of
infection that chest radiography was the most cost-
effective screening modality although the TST strategyprevented the most cases of TB. By contrast, Dasgupta
et al. constructed a Markov model informed by empir-
ical data to compare the cost effectiveness of screening
migrants with chest radiography pre-arrival followed by
TST (if the CXR showed any abnormalities) with screen-
ing close contacts of index sputum smear-positive cases
(with TST followed by CXR) [77]. The authors found
that migrant screening using chest radiography was not
cost-effective due to difficulties with operationalising
screening [77]. The lack of research in this area high-
lights the need for further health-economic analyses to
objectively assess, and make conclusions about, the cost-
effectiveness of screening migrants for active TB.
A larger number of published studies from high-
income countries have focused on evaluating the cost-
effectiveness of screening migrants for LTBI [78–86].
These studies, which have evaluated different aspects of
LTBI screening including which migrants to screen and
how to screen, have generally concluded that LTBI
screening of migrants from high burden countries,
mainly Asia and Africa is a cost-effective intervention in
high-income countries [41, 42, 78–86].
Methods for diagnosing LTBI have evolved over the
last decade with IGRAs increasingly replacing the
TST [87]. This is reflected by the several studies
which have explored the relative cost-effectiveness of
different screening modalities and algorithms for LTBI
[41, 42, 79–84]. These health-economic analyses have,
in general, found that IGRA are more cost-effective
than TST [41, 42, 79, 81, 84]. However, in the ab-
sence of robust longitudinal data as for TST, there re-
mains ongoing debate about the use of IGRA as a
screening tool with certain national guidelines instead
advocating the use of TST [13].
Limitations of cost-effectiveness studies
The scarcity of randomised clinical trials has meant that
policy decision are mostly based on of health-economic
modelling and observational data. However models must,
by definition, make a number of simplifying assumptions
and their results are therefore highly dependent on model
structure and specific model parameters – even if there is
uncertainty around these due to a lack of empirical data.
Future directions
The impact of migration on tuberculosis epidemiology
in high-income countries is increasingly well-recognised
and there has been a shift towards augmenting TB con-
trol by screening migrants for TB. Up until recently
there has been a lack of coordinated international guid-
ance in this area but the European Centre for Disease
Prevention and Control (ECDC) is currently formulating
guidance on the screening of migrants for a range of
infectious diseases – including TB [88]. As migrant
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trol programmes, there will be an increasing need for
high-quality operational research to establish how to
undertake TB screening most effectively and integrate it
with migrant health programmes including testing for
blood-borne viruses.
Conclusions
In this review we have comprehensively brought to-
gether the literature with respect to all aspects of tuber-
culosis and migration. Tuberculosis in high-income
countries continues to be a cause of morbidity and
mortality – particularly amongst individuals who have
been born overseas in high TB burden, low-income
countries and migrated to high-income countries. The
reasons for the burden of disease in the foreign-born,
migrant, population are primarily due to migration from
high TB burden settings and the reactivation of
remotely-acquired latent TB infection. As a consequence
there is increasing focus on how best to enhance TB
control through the coordinated screening of migrants
for TB. Whilst most countries focus on screening mi-
grants for active TB, this has a relatively low yield on its
own and it is likely that the most effective and cost-
effective means of screening migrants for TB will
comprise multiple, inter-linking elements: pre-arrival
screening for active TB and targeted post arrival screen-
ing for LTBI in migrants from intermediate/high TB
burden settings. However, the programmatic implemen-
tation of migrant screening is potentially hampered by
limited uptake, acceptance and completion of therapy.
There is an urgent need for further coordinated research
in this area to inform future national and international
guidance.
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